Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
A variety of compounds having a benzopyran such as levcromakalim generally exhibit potent antihypertensive activity. During extensive investigations aimed toward identifying K+ channel openers having selective coronary vasodilation without potent hypotensive and tachycardiac effects, we synthesized a series of 3,4-dihydro-2H-1-benzopyran-3-ol derivatives modified at positions 2, 4, and 6 in the benzopyran ring. Initially, compounds having two methoxymethyl groups at position 2 were found to show a selective effect on coronary blood flow (CoBF) relative to mean arterial pressure (MAP) in anesthetized dogs. To find more potent vasodilators, various benzopyran derivatives modified at position 4 were synthesized and structure-activity relationships were examined by evaluation of the extent and duration of the increase in CoBF in anesthetized dogs. As a result, compounds having a (1,6-dihydro-6-oxopyridazin-3-yl)amino group at position 4, in addition to the two methoxymethyl groups at position 2, were found to be more potent and to have an improved duration of action. Among these compounds, JTV-506, (-)-(3S,4R)-6-cyano-3,4-dihydro-4-[(1,6-dihydro-1-methyl-6-oxopyridaz in-3-yl)amino]-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol, exhibited good selectivity for its effect. Administration of this compound (0.03 mg/kg, p.o.) elicited an increase of CoBF without a change of systemic blood pressure and heart rate (HR) in conscious dogs. Further evaluation was performed with respect to (i) the selectivity of its action on the coronary artery versus the aorta and (ii) its effects on MAP, HR, and electrocardiographic ST elevation. As a result, JTV-506 was selected as a potent and selective coronary vasodilator with various pharmacological features favoring clinical development.
Cho
H
H
Japan Tobacco Inc., Central Pharmaceutical Research Institute, Osaka, Japan.
Katoh
S
S
Sayama
S
S
Murakami
K
K
Nakanishi
H
H
Kajimoto
Y
Y
Ueno
H
H
Kawasaki
H
H
Aisaka
K
K
Uchida
I
I
D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D015640:Ion Channel Gating / Q000187:drug effects*; D008297:Male; D008958:Models, Molecular; D015394:Molecular Structure; D015221:Potassium Channels / Q000502:physiology*; D011724:Pyridazines / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship; D013552:Swine; D014665:Vasodilator Agents / Q000138:chemical synthesis* / Q000494:pharmacology
C101617:6-cyano-3,4-dihydro-4-((1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl)amino)-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol; D001578:Benzopyrans; D015221:Potassium Channels; D011724:Pyridazines; D014665:Vasodilator Agents